Liver disease accounts for two million deaths annually and is responsible for 4% of all
deaths (1 out of every 25 deaths worldwide); approximately two-thirds of all liver-related …

Given the increasing prevalence of diabetes and obesity worldwide, the deleterious effects
of non-alcoholic fatty liver disease (NAFLD) are becoming a growing challenge for public …

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved
treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo …

Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects
approximately one-quarter of the global adult population, causing a substantial burden of ill …

Liver is the largest solid organ in the body that performs over 100 functions. It removes the
toxins and waste products from the blood stream, maintains healthy blood sugar levels …

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease worldwide. The
estimated global incidence of NAFLD is 47 cases per 1,000 population and is higher among …

Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …

Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …